• 1
    Finucane ML, Slovic P, Mertz CK. Public perception of the risk of blood transfusion. Transfusion 2000; 40:101722.
  • 2
    van Hulst M, de Wolf JT, Staginnus U, Ruitenberg EJ, Postma MJ. Pharmaco-economics of blood transfusion safety: review of the available evidence. Vox Sang 2002; 83:14655.
  • 3
    Practice strategies for elective red blood cell transfusion. American College of Physicians. Ann Intern Med 1992; 116:4036.
  • 4
    Goodnough LT, Brecher ME, Kanter MH, AuBuchon J. P. Transfusion medicine. Second of two parts–blood conservation. N Engl J Med 1999; 340:52533.
  • 5
    Practice Guidelines for blood component therapy: A report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology 1996; 84:73247.
  • 6
    Fergusson D, Blair A, Henry D, et al. Technologies to minimize blood transfusion in cardiac and orthopedic surgery. Results of a practice variation survey in nine countries. International Study of Peri-operative Transfusion (ISPOT) Investigators. Int J Technol Assess Health Care 1999; 15:71728.
  • 7
    Drummond M, Brandt A, Luce B, Rovira J. Standardizing methodologies for economic evaluation in health care. Practice, problems, and potential. Int J Technol Assess Health Care 1993; 9:2636.
  • 8
    Drummond M. F., O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. Oxford : Oxford University Press, 1997.
  • 9
    Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York : Oxford University Press, 1996.
  • 10
    Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276:11727.
  • 11
    Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276:133941.
  • 12
    Siegel JE, Torrance G. W., Russell LB, Luce BR, Weinstein MC, Gold MR. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine. Pharmacoeconomics 1997; 11:15968.
  • 13
    Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996; 276:12538.
  • 14
    Berggren F, Andersson F. Health economic guidelines–similarities, differences and some implications. Value Health 2001; 4:22550.
  • 15
    Weinstein MC, Siegel JE, Garber AM, et al. Productivity costs, time costs and health-related quality of life: a response to the Erasmus Group. Health Econ 1997; 6:50510.
  • 16
    Brouwer WB, Koopmanschap MA, Rutten F. F. Productivity costs measurement through quality of life? A response to the recommendation of the Washington Panel. Health Econ 1997; 6:2539.
  • 17
    Brouwer WB, Koopmanschap MA, Rutten F. F. Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion. Health Econ 1997; 6:5114.
  • 18
    Owens DK. Interpretation of cost-effectiveness analyses. J Gen Intern Med 1998; 13:7167.
  • 19
    Jefferson T, Demicheli V, Mugford M. Elementary Economic Evaluation in Health Care. London : BMJ Publishing Group, 1996.
  • 20
    Birkmeyer JD, Goodnough LT, AuBuchon J. P., et al. The cost-effectiveness of preoperative autologous blood donation for total hip and knee replacement. Transfusion 1993; 33:54451.
  • 21
    Birkmeyer JD, AuBuchon J, Littenberg B, et al. Cost-effectiveness of preoperative autologous donation in coronary artery bypass grafting. Ann Thorac Surg 1994; 57:1619.
  • 22
    Etchason J, Petz L, Keeler E, et al. The cost effectiveness of preoperative autologous blood donations. N Engl J Med 1995; 332:71924.
  • 23
    Huber TS, McGorray S. P., Carlton LC, et al. Intraoperative autologous transfusion during elective infrarenal aortic reconstruction: a decision analysis model. J Vasc Surg 1997; 25:98493.
  • 24
    Kilgore ML, Pacifico AD. Shed mediastinal blood transfusion after cardiac operations: a cost-effectiveness analysis. Ann Thorac Surg 1998; 65:124854.
  • 25
    Barosi G, Marchetti M, Liberato NL. Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. Br J Cancer 1998; 78:7817.
  • 26
    Coyle D, Lee KM, Fergusson DA, Laupacis A. Cost effectiveness of epoetin-alpha to augment preoperative autologous blood donation in elective cardiac surgery. Pharmacoeconomics 2000; 18:16171.
  • 27
    Sonnenberg FA, Gregory P, Yomtovian R, et al. The cost-effectiveness of autologous transfusion revisited: implications of an increased risk of bacterial infection with allogeneic transfusion. Transfusion 1999; 39:80817.
  • 28
    Ray MJ, Brown K. F., Burrows CA, O'Brien M. F. Economic evaluation of high-dose and low-dose aprotinin therapy during cardiopulmonary bypass. Ann Thorac Surg 1999; 68:9405.
  • 29
    Marchetti M, Barosi G. Cost-effectiveness of epoetin and autologous blood donationin reducing allogeneic blood transfusions incoronary artery bypass graft surgery. Transfusion 2000; 40:67381.
  • 30
    Jackson BR, Umlas J, AuBuchon J. The cost-effectiveness of postoperative recovery of RBCs in preventing transfusion-associated virus transmission after joint arthtoplasty. Transfusion 2000; 40:10636.
  • 31
    Coyle D, Lee KM, Fergusson DA, Laupacis A. Economic analysis of erythropoietin use in orthopaedic surgery. Transfus Med 1999; 9:2130.
  • 32
    Dignan RJ, Law D. W., Seah P. W., et al. Ultra-low dose aprotinin decreases transfusion requirements and is cost effective in coronary operations. Ann Thorac Surg 2001; 71:15863.
  • 33
    Ray MJ, O'Brien M. F. Comparison of epsilon aminocaproic acid and low-dose aprotinin in cardiopulmonary bypass: efficiency, safety and cost. Ann Thorac Surg 2001; 71:83843.
  • 34
    Horowitz NS, Gibb RK, Menegakis NE, Mutch DG, Rader JS, Herzog TJ. Utility and cost-effectiveness of preoperative autologous blood donation in gynecologic and gynecologic oncology patients. Obstet Gynecol 2002; 99:7716.
  • 35
    Robinson D, Bliss E. A model of the direct and indirect effects of aprotinin administration on the overall costs of coronary revascularization surgery in a university teaching hospital cardiothoracic unit. Clin Ther 2002; 24:167789.
  • 36
    Goodnough LT, Monk TG, Brecher ME. Autologous blood procurement in the surgical setting: lessons learned in the last 10 years. Vo x Sang 1996; 71:13341.
  • 37
    Faught C, Wells P, Fergusson D, Laupacis A. Adverse effects of methods for minimizing perioperative allogeneic transfusion: a critical review of the literature. Transfus Med Rev 1998; 12:20625.
  • 38
    Vamvakas EC, Carven JH. Transfusion and postoperative pneumonia in coronary artery bypass graft surgery: effect of the length of storage of transfused red cells. Transfusion 1999; 39:70110.
  • 39
    Vamvakas EC, Carven JH. Length of storage of transfused red cells and postoperative morbidity in patients undergoing coronary artery bypass graft surgery. Transfusion 2000; 40:1019.
  • 40
    Vamvakas EC, Blajchman MA. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction Blood 2001; 97:118095.
  • 41
    Leal-Noval SR, Rincon-Ferrari MD, Garcia-Curiel A, et al. Transfusion of blood components and postoperative infection in patients undergoing cardiac surgery. Chest 2001; 119:14618.
  • 42
    Chelemer SB, Prato BS, Cox PM Jr, O'Connor GT, Morton JR. Association of bacterial infection and red blood cell transfusion after coronary artery bypass surgery. Ann Thorac Surg 2002; 73:13842.
  • 43
    D'Ambra MN, Gray RJ, Hillman R, et al. Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients. Ann Thorac Surg 1997; 64:168693.
  • 44
    Sowade O, Warnke H, Scigalla P, et al. Avoidance of allogeneic blood transfusions by treatment with epoetin beta (recombinant human erythropoietin) in patients undergoing open- heart surgery. Blood 1997; 89:4118.
  • 45
    Goldberg MA, McCutchen J. W., Jove M, et al. A safety and efficacy comparison study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery. Am J Orthop 1996; 25:54452.
  • 46
    Goodnough LT, Despotis GJ, Parvin CA. Erythropoietin therapy in patients undergoing cardiac operations. Ann Thorac Surg 1997; 64:157980.
  • 47
    Henry DA, Moxey AJ, Carless PA, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2001; CD001886.
  • 48
    Muller-Breitkreutz K. Results of viral marker screening of unpaid blood donations and probability of window period donations in 1997 EPFA Working Group on Quality Assurance. Vox Sang 2000; 78:14957.
  • 49
    Loubiere S, Rotily M, Durand-Zaleski I, Costagliola D. Including polymerase chain reaction in screening for hepatitis C virus RNA in blood donations is not cost-effective. Vo x Sang 2001; 80:199204.
  • 50
    Heiss MM, Mempel W, Jauch K. W., et al. Beneficial effect of autologous blood transfusion on infectious complications after colorectal surgery. Lancet 1993; 342:132833.
  • 51
    Innerhofer P, Walleczek C, Luz G. Transfusion of buffy-coat-depleted blood components and risk of postoperative infection in orthopedic patients. Transfusion 1999; 39:62532.
  • 52
    Hebert PC, Fergusson D, Blajchman MA, et al. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA 2003;289:1941.
  • 53
    Pereira A. Deleterious consequences of allogenic blood transfusion on postoperative infection: really a transfusion-related immunomodulation effect Blood 2001; 98:498500.
  • 54
    Michel BC, van Hout BA, Bonsel GJ. Assessing the benefits of transplant services. Baillieres Clin Gastroenterol 1994; 8:41123.
  • 55
    Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995; 15:36990.
  • 56
    Al MJ, Koopmanschap MA, van Enckevort PJ, et al. Cost-effectiveness of lung transplantation in The Netherlands: a scenario analysis. Chest 1998; 113:12430.
  • 57
    Hoffer S, Berardino F, Smith J, Rubin S. Economic Values for Evaluation of FAA Investment and Regulatory Decisions. Washington , DC : Federal Aviation Administration, Office of Aviation Policy, Plans, and Management Analysis Publication FAA-APO-98–8, 1998.